 HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 25, 2021 GLOBE NEWSWIRE -- HUTCHMED China Limited HUTCHMED NasdaqAIM: HCM; HKEX:13 has initiated a Phase IbII study of fruquintinib in combination with BeiGenes tislelizumab in patients with advanced triple negative breast cancer TNBC or advanced endometrial cancer EC in the U.S. The first patient was dosed on August 24, 2021. This trial is to explore the potential for the addition of a highly selective vascular endothelial growth factor receptor VEGFR inhibitor, fruquintinib, to anti-programmed death-1 PD-1 antibody tislelizumab in inducing activity to immune checkpoint inhibitors. 